Travere Therapeutics (TVTX) is back in focus after being named IBD Stock Of The Day, with recent coverage centering on progress for its kidney disease treatment Filspari and the resulting pickup in investor attention.

At a share price of $65.71, Travere Therapeutics has seen strong momentum recently, with a 30 day share price return of 16.8% and a 1 year total shareholder return of 266.69%, suggesting that investors are reassessing both growth prospects and risk.

If you are watching how interest in Travere Therapeutics is building, this can be a useful moment to scan for other healthcare opportunities using the 41 healthcare AI stocks.

After a sharp re rating and with Travere Therapeutics still trading below average analyst targets and internal fair value estimates, is the market being sensibly cautious about Filspari and the broader pipeline, or overly conservative on what is already known?

Most Popular Narrative: 3.9% Undervalued

Travere Therapeutics is trading at $65.71, a touch below the most widely followed fair value estimate of $68.36, which anchors on long term rare kidney disease potential and portfolio durability.

Expansion of FILSPARI's label to include treatment for FSGS, a rare kidney disease with no approved therapies, positions Travere for first-mover advantage in a large, underserved market, if approved, this will create a new, high-margin revenue stream and significantly expand the company's addressable market. (Revenue growth, gross margins)

Investors may want to see what kind of revenue curve and margin profile the potential FSGS indication and the broader FILSPARI rollout would need to support that valuation. The narrative leans heavily on sustained top line growth, higher profitability, and a future earnings multiple that reflects execution similar to a mature rare disease leader rather than an early stage biotech. It can be useful to examine what those assumptions look like when they are laid out year by year and discounted back to today.

Result: Fair Value of $68.36 (UNDERVALUED)

However, Travere Therapeutics still faces real pressure points, including heavier reliance on FILSPARI and potential competition or regulatory delays that could quickly challenge this 3.9% undervaluation story.

Another View on Travere Therapeutics: Sales Multiple Sends a Different Signal

While the analyst narrative frames Travere Therapeutics as 3.9% undervalued on future earnings and cash flows, the current P/S ratio of 10.5x tells a tighter story. It is higher than the stock's own fair ratio of 8.4x and above peer averages of 7.6x, which points to less room for error if the growth path changes.

For a closer look at how that sales multiple compares with what the numbers imply as a fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment around Travere Therapeutics turning more optimistic, this is a good point to review the underlying data yourself and decide how comfortable you are with the current setup. To see what investors are finding encouraging, take a closer look at the 3 key rewards.

Looking for more investment ideas beyond Travere Therapeutics?

If Travere Therapeutics has your attention, do not stop your research here. Broader context across sectors and styles can sharpen how you view any single stock.

• Spot potential mispriced opportunities early and compare them with Travere using the 48 high quality undervalued stocks.
• Prioritize resilience in tougher markets by reviewing companies in the 77 resilient stocks with low risk scores.
• Hunt for underfollowed businesses with solid fundamentals through the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.